Botulinum Toxin vs Palmitoyl Tetrapeptide-7
A side-by-side research comparison of Botulinum Toxin and Palmitoyl Tetrapeptide-7 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Botulinum Toxin | Palmitoyl Tetrapeptide-7 |
|---|---|---|
| Full name | Botulinum Toxin Type A (Botox) | Palmitoyl Tetrapeptide-7 (Pal-GQPR) |
| Category | Skin & Anti-Aging | Skin & Anti-Aging |
| Status | FDA-approved drug (prescription) | Research compound |
| Mechanism | Cleaves SNARE proteins (SNAP-25) required for acetylcholine release at the neuromuscular junction, temporarily blocking nerve signals to targeted muscles. This relaxes the muscle, softening dynamic wrinkles or reducing overactivity. | Inhibits IL-6 release from keratinocytes and reduces inflammation-mediated MMP activation, preserving existing collagen while complementing Pal-GHK collagen building. |
| Molecular weight | ~150 kDa | 693 Da |
| Half-life | Effects last ~3-4 months (local) | 8-12 hours (topical) |
| Bioavailability | Local intramuscular/intradermal injection | Good (topical) |
| Typical dose | Units per treatment area (clinical) | 2-4% in formulation |
| Frequency | Every ~3-4 months | 1-2x daily |
| Route | Injection by a professional | Topical |
Botulinum Toxin reported benefits
- Temporarily smooths dynamic wrinkles
- Treats muscle overactivity (medical)
- Reduces excessive sweating (medical)
- Migraine prevention (medical)
Palmitoyl Tetrapeptide-7 reported benefits
- Anti-inflammatory (skin)
- Reduces IL-6
- Prevents collagen degradation
- Combats inflammaging
Related comparisons
Research and educational reference only. Not medical advice.